Loading
Enanta Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Feb 2025.
Enanta Pharmaceuticals Inc: what insiders have been doing
This page follows insider dealings at Enanta Pharmaceuticals Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 22 filings signed by 8 insiders.
All open-market trades in the period are sales: 7 sales worth €150k, by 7 insiders, with no purchase on record. Biggest ticket of the year: €58k, sold by Luly Jay R. and made public on 5 December 2025.
With 22 filings in twelve months, the company is more active than the median of 19 filings across the 5,816 companies we follow on the same exchange. The full history, which starts in 2016, counts 1 purchase against 25 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 September 2025), the company reported revenue of 65.3 m USD and net income of -81.9 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
131
Thresholds
n/a
Buy Volume
€247,034
1 ops. · all time
Sell Volume
€1M
25 ops. · all time
Who traded when
BuySaleJay R. Luly1 buy2 sales
Brendan Luu2 sales
Scott T. Rottinghaus2 sales
Tara Lynn Kieffer2 sales
Yat Sun Or2 sales
Harry R. Trout III1 sale
+2 other insiders
Since the insiders bought
- +84.7%Entry US$7.50 · Close at T+365 US$13.85
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended September 2025 · cache
US$11.47
Analyst consensus
6 analysts1.17/5
US$19.00Target US$21.83(+90%)US$32.00
Income statement
RevenueUS$65.3M
EBITDA-US$71.3M-109% margin
Net income-US$81.9M-96.9% margin
Valuation
PER (forward)-4.8x
P/Book3.3x
Beta0.96
Balance sheet & cash
Market capUS$334.1M
Total debtUS$57.9M
Free Cash Flow-US$32.2M
Debt / Equity180%
Profitability & ownership
ROE-70.1%
ROA-12.3%
% insiders4.7%
% institutions94.4%
Last declaration on 10 August 2026
Declarations131 total
1,467 shares@ US$13.340.0056% mcap15.3% of flowCommon StockSEC:0002064832-26-000266:0
1,318 shares0Common StockSEC:0002064832-26-000016:0
1,575 shares0Common StockSEC:0002064832-26-000012:0
1,650 shares0Common StockSEC:0002064832-26-000010:0
1,650 shares0Common StockSEC:0002064832-26-000008:0
4,800 shares0Common StockSEC:0002064832-26-000006:0
1,575 shares0Common StockSEC:0002064832-26-000014:0
323 shares@ US$14.2379.2% of flowCommon StockSEC:0002064832-25-000070:0
542 shares@ US$14.2383.8% of flowCommon StockSEC:0002064832-25-000067:0
798 shares@ US$14.238.8% of flowCommon StockSEC:0002064832-25-000065:0
1,394 shares@ US$14.2318.3% of flowCommon StockSEC:0002064832-25-000063:0
2,106 shares@ US$14.2313.7% of flowCommon StockSEC:0002064832-25-000061:0
2,390 shares@ US$14.237.8% of flowCommon StockSEC:0002064832-25-000059:0
4,743 shares@ US$14.232.6% of flowCommon StockSEC:0002064832-25-000057:0
85 shares@ US$14.1220.8% of flowCommon StockSEC:0002064832-25-000053:0
105 shares@ US$14.1216.2% of flowCommon StockSEC:0002064832-25-000050:0
498 shares@ US$14.126.5% of flowCommon StockSEC:0002064832-25-000048:0
753 shares@ US$14.124.9% of flowCommon StockSEC:0002064832-25-000046:0
753 shares@ US$14.122.4% of flowCommon StockSEC:0002064832-25-000044:0
1,885 shares@ US$14.121.0% of flowCommon StockSEC:0002064832-25-000042:0
6,463 shares0Common StockSEC:0002064832-25-000036:0
3,163 shares0Common StockSEC:0002064832-25-000038:0
2,217 shares@ US$6.9912.0% of flowCommon StockSEC:0001062993-25-013981:0
7,500 shares0Common StockSEC:0001062993-25-002563:0
7,500 shares0Common StockSEC:0001062993-25-002553:0
25 of 131 declarations
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc. is a U.S.-listed biotechnology company traded on the NASDAQ Global Select Market, headquartered in Watertown, Massachusetts, United States. Founded in 1995, Enanta was built around chemistry-driven drug discovery and initially established its credibility through virology collaborations, most notably with AbbVie. Those collaborations led to protease inhibitor compounds incorporated into commercial hepatitis C regimens, which still matter today because Enanta continues to receive royalty revenue from AbbVie’s HCV franchise. That mix of legacy royalties and internal R&D makes Enanta a hybrid story: part cash-generating biotech asset, part clinical-stage pipeline company. ([enanta.com](https://www.enanta.com/about/about-us/?utm_source=openai))
The company’s current strategic focus is concentrated in two main therapeutic areas: respiratory virology and immunology. In virology, Enanta is advancing a portfolio centered on respiratory syncytial virus (RSV), including zelicapavir and EDP-323, alongside earlier antiviral efforts. In immunology, Enanta is building an oral small-molecule pipeline aimed at key drivers of type 2 inflammation, with programs targeting KIT, STAT6, and MRGPRX2. This is an important positioning point for investors: Enanta is not trying to compete as a broad diversified pharma company, but rather as a specialist developer of differentiated oral therapies with a scientific edge in small-molecule design. ([enanta.com](https://www.enanta.com/pipeline/pipeline-overview/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Enanta sits in a challenging but potentially attractive niche. It lacks the scale of large-cap pharmaceutical peers, but it has clear expertise in medicinal chemistry, a defined pipeline, and a track record of translating discovery work into partnered and commercialized assets. The investment case therefore depends heavily on clinical execution, regulatory milestones, and the ability to create strategic partnerships when appropriate. The company has also emphasized that its royalty stream and cash resources support ongoing development activities, which is particularly relevant for a clinical biotech with multiple programs in motion. ([ir.enanta.com](https://ir.enanta.com/static-files/55c69228-2c8a-429c-aabf-d8f7990d72f5))
Recent developments have been meaningful. In 2025, Enanta reported that it met target enrollment in the RSVHR Phase 2 study of zelicapavir, with topline data expected later in the year. It also continued advancing its STAT6 program, with a development candidate selection targeted for the second half of 2025, while IND-enabling work progressed for its KIT inhibitor program. In May 2025, management reported cash, cash equivalents and marketable securities of $193.4 million at March 31, 2025, further bolstered by a federal tax refund received in April 2025. For investors, ENTA is therefore a U.S. NASDAQ biotech name with meaningful pipeline catalysts, recurring royalty support, and a profile that is highly sensitive to clinical and regulatory execution. ([ir.enanta.com](https://ir.enanta.com/static-files/55c69228-2c8a-429c-aabf-d8f7990d72f5))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
